A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
Primary Purpose
Asthma
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
dupilumab
Matching placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma
Eligibility Criteria
Key Inclusion Criteria:
- A physician diagnosis of asthma
- Pre-bronchodilator FEV1 between 30% and 75% predicted at both the screening and baseline visits
- Bronchodilator reversibility defined as >200 mL and 12% increase in FEV1 post-administration of a short-acting beta agonist (SABA). A patient may also qualify if there is a documented history of bronchodilator reversibility or positive methacholine challenge test within 12 months prior to the screening visit
- Stable background therapy for at least 3 months with a stable dose ≥4 weeks prior to the baseline visit of a medium-to-high dose ICS (fluticasone propionate ≥250 to 1000 μg twice daily [BID] or equivalent) in combination with at least a second controller medication (eg, long-acting beta agonist [LABA], long-acting muscarinic antagonist [LAMA], leukotriene receptor antagonist [LTRA], theophylline, etc.); a third controller is allowed and with the same stabilization requirements
- Blood eosinophil count ≥300 cells/μL for patients not on maintenance OCS at the screening visit
- ACQ-5 score ≥1.5 at the screening and baseline visits
Key Exclusion Criteria:
- Body mass index >35 kg/m2 at screening
- Current smoking, vaping or tobacco chewing or cessation of any of these within 6 months prior to randomization, or >10 pack years smoking history
- Patients who require supplemental oxygen at screening
- Clinically significant cardiac disease as described in the protocol
- Uncontrolled hypertension at screening or baseline
- Participation in exercise or physical rehabilitation program within last 6 months prior to screening or planned during the study
- Previous use of dupilumab
- Anti-IgE therapy (eg, omalizumab [Xolair®]) within 130 days prior to visit 1 or any other biologic therapy (including anti-IL5, anti-IL-5R, anti-IL4Rα, anti-IL-13 mAb) or systemic immunosuppressant (eg, methotrexate, any anti-tumor necrosis factor mAbs, Janus kinase inhibitors, B- and/or T-cell targeted immunosuppressive therapies) to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 3 months or 5 half-lives prior to screening, whichever is longer
- Exposure to another investigative drug (monoclonal antibodies as well as small molecules) within a period prior to screening, of <3 months or <5 half-lives (whichever is longer)
- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
- Women of childbearing potential (WOCBP)* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose
NOTE: Other protocol defined inclusion/exclusion criteria apply
Sites / Locations
- Palos Verdes Medical Group (PVMG); Peninsula Research Associates (PRA)
- UCLA Medical Center - Harbor
- Allianz Research Institute
- University of Iowa Hospitals & Clinics-Roy J. and Lucille A. Carver College of Medicine
- University Of Kansas Medical Center
- Infinity Medical Research
- University of Michigan
- American Health Research
- UH Cleveland Medical Center
- Temple University Hospital
- Regeneron Study Site
- The University of Texas Medical School at Houston
- Intermountain Medical Center
- CHU Dijon
- CHU Reims
- CHU de Strasbourg - Nouvel Hopital Civil
- Praxis Dr. M. Rolke u. Dr. P. Rueckert
- Regeneron Study Site
- IKF Pneumologie GmbH & Co. KG - Institut fuer klinische Forschung Pneumologie Frankfurt (Clinical Research Centre Respiratory Medicine) to IKF Pneumologie Frankfurt GmbH & Co KG.
- Regeneron Study Site
- Regeneron Study Site
- IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz
- Regeneron Study Site
- KLB - Gesundheitsforschung Luebeck GmbH
- Regeneron Study Site
- Regeneron Study Site
- Centrum Medycyny Oddechowej, Mroz Spolka Jawna
- Lekarze Specjalisci - J. Malolepszy i Partnerzy
- Hospital Universitario de Bellvitge
- Hospital General Universitario Gregorio Maranon (HGUGM) - Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM)
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
dupilumab
Matching placebo
Arm Description
A loading dose at the start of the treatment followed by once every two weeks (Q2W).
Matching dupilumab
Outcomes
Primary Outcome Measures
Change in constant work rate exercise endurance time
Secondary Outcome Measures
Change in average number of steps walked per day
Based on accelerometry data
Change in total energy expenditure
Metabolic equivalents of tasks [METs]. Based on accelerometry data
Change in the mean duration of moderate-to-vigorous physical activity
Defined as ≥3 METs. Based on accelerometry data
Change in pre- and post-exercise Forced Expiratory Volume in One Second (FEV1)
Based on spirometry data
Full Information
NCT ID
NCT04203797
First Posted
December 17, 2019
Last Updated
September 5, 2023
Sponsor
Regeneron Pharmaceuticals
1. Study Identification
Unique Protocol Identification Number
NCT04203797
Brief Title
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
Official Title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Patients With Moderate-to-Severe Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
July 16, 2020 (Actual)
Primary Completion Date
July 15, 2023 (Actual)
Study Completion Date
July 15, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Regeneron Pharmaceuticals
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary objective of the study is to demonstrate that dupilumab treatment improves exercise capacity in patients with moderate-to-severe asthma.
The secondary objectives of the study are:
To demonstrate that dupilumab treatment increases physical activity of daily living in patients with moderate-to-severe asthma
To demonstrate that dupilumab treatment improves pre- and post-exercise lung function in patients with moderate-to-severe asthma
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
dupilumab
Arm Type
Experimental
Arm Description
A loading dose at the start of the treatment followed by once every two weeks (Q2W).
Arm Title
Matching placebo
Arm Type
Experimental
Arm Description
Matching dupilumab
Intervention Type
Drug
Intervention Name(s)
dupilumab
Other Intervention Name(s)
Dupixent®, SAR231893
Intervention Description
Pre-filled syringe administered by subcutaneous (SC) injections
Intervention Type
Drug
Intervention Name(s)
Matching placebo
Intervention Description
Pre-filled syringe administered by subcutaneous (SC)
Primary Outcome Measure Information:
Title
Change in constant work rate exercise endurance time
Time Frame
Up to week 12
Secondary Outcome Measure Information:
Title
Change in average number of steps walked per day
Description
Based on accelerometry data
Time Frame
Up to week 12
Title
Change in total energy expenditure
Description
Metabolic equivalents of tasks [METs]. Based on accelerometry data
Time Frame
Up to week 12
Title
Change in the mean duration of moderate-to-vigorous physical activity
Description
Defined as ≥3 METs. Based on accelerometry data
Time Frame
Up to week 12
Title
Change in pre- and post-exercise Forced Expiratory Volume in One Second (FEV1)
Description
Based on spirometry data
Time Frame
Up to week 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria:
A physician diagnosis of asthma
Pre-bronchodilator FEV1 between 30% and 75% predicted at both the screening and baseline visits
Bronchodilator reversibility defined as >200 mL and 12% increase in FEV1 post-administration of a short-acting beta agonist (SABA). A patient may also qualify if there is a documented history of bronchodilator reversibility or positive methacholine challenge test within 12 months prior to the screening visit
Stable background therapy for at least 3 months with a stable dose ≥4 weeks prior to the baseline visit of a medium-to-high dose ICS (fluticasone propionate ≥250 to 1000 μg twice daily [BID] or equivalent) in combination with at least a second controller medication (eg, long-acting beta agonist [LABA], long-acting muscarinic antagonist [LAMA], leukotriene receptor antagonist [LTRA], theophylline, etc.); a third controller is allowed and with the same stabilization requirements
Blood eosinophil count ≥300 cells/μL for patients not on maintenance OCS at the screening visit
ACQ-5 score ≥1.5 at the screening and baseline visits
Key Exclusion Criteria:
Body mass index >35 kg/m2 at screening
Current smoking, vaping or tobacco chewing or cessation of any of these within 6 months prior to randomization, or >10 pack years smoking history
Patients who require supplemental oxygen at screening
Clinically significant cardiac disease as described in the protocol
Uncontrolled hypertension at screening or baseline
Participation in exercise or physical rehabilitation program within last 6 months prior to screening or planned during the study
Previous use of dupilumab
Anti-IgE therapy (eg, omalizumab [Xolair®]) within 130 days prior to visit 1 or any other biologic therapy (including anti-IL5, anti-IL-5R, anti-IL4Rα, anti-IL-13 mAb) or systemic immunosuppressant (eg, methotrexate, any anti-tumor necrosis factor mAbs, Janus kinase inhibitors, B- and/or T-cell targeted immunosuppressive therapies) to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis) and other diseases, within 3 months or 5 half-lives prior to screening, whichever is longer
Exposure to another investigative drug (monoclonal antibodies as well as small molecules) within a period prior to screening, of <3 months or <5 half-lives (whichever is longer)
Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study
Women of childbearing potential (WOCBP)* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 12 weeks after the last dose
NOTE: Other protocol defined inclusion/exclusion criteria apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials Management
Organizational Affiliation
Regeneron Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Palos Verdes Medical Group (PVMG); Peninsula Research Associates (PRA)
City
Rolling Hills Estates
State/Province
California
ZIP/Postal Code
90274
Country
United States
Facility Name
UCLA Medical Center - Harbor
City
Torrance
State/Province
California
ZIP/Postal Code
90509
Country
United States
Facility Name
Allianz Research Institute
City
Westminster
State/Province
California
ZIP/Postal Code
92683
Country
United States
Facility Name
University of Iowa Hospitals & Clinics-Roy J. and Lucille A. Carver College of Medicine
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
University Of Kansas Medical Center
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
Infinity Medical Research
City
North Dartmouth
State/Province
Massachusetts
ZIP/Postal Code
02747
Country
United States
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
American Health Research
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28277
Country
United States
Facility Name
UH Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Temple University Hospital
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Facility Name
Regeneron Study Site
City
Hendersonville
State/Province
Tennessee
ZIP/Postal Code
37075
Country
United States
Facility Name
The University of Texas Medical School at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Intermountain Medical Center
City
Murray
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Facility Name
CHU Dijon
City
Dijon
State/Province
Bourgogne
ZIP/Postal Code
21000
Country
France
Facility Name
CHU Reims
City
Reims
State/Province
Marne
ZIP/Postal Code
51092
Country
France
Facility Name
CHU de Strasbourg - Nouvel Hopital Civil
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
Praxis Dr. M. Rolke u. Dr. P. Rueckert
City
Aschaffenburg
State/Province
Bavaria
ZIP/Postal Code
63739
Country
Germany
Facility Name
Regeneron Study Site
City
Frankfurt am Main
State/Province
Hessen
ZIP/Postal Code
60389
Country
Germany
Facility Name
IKF Pneumologie GmbH & Co. KG - Institut fuer klinische Forschung Pneumologie Frankfurt (Clinical Research Centre Respiratory Medicine) to IKF Pneumologie Frankfurt GmbH & Co KG.
City
Frankfurt am Main
State/Province
Hessen
ZIP/Postal Code
60596
Country
Germany
Facility Name
Regeneron Study Site
City
Hannover
State/Province
Lower Saxony
ZIP/Postal Code
30625
Country
Germany
Facility Name
Regeneron Study Site
City
Koblenz
State/Province
Rheinland-Pfalz
ZIP/Postal Code
56068
Country
Germany
Facility Name
IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz
City
Mainz
State/Province
Rheinland-Pfalz
ZIP/Postal Code
55128
Country
Germany
Facility Name
Regeneron Study Site
City
Grosshansdorf
State/Province
Schleswig-Holstein
ZIP/Postal Code
22977
Country
Germany
Facility Name
KLB - Gesundheitsforschung Luebeck GmbH
City
Luebeck
State/Province
Schleswig-Holstein
ZIP/Postal Code
486344
Country
Germany
Facility Name
Regeneron Study Site
City
Berlin
ZIP/Postal Code
12159
Country
Germany
Facility Name
Regeneron Study Site
City
Lubin
State/Province
Dolnoslaskie
ZIP/Postal Code
59-300
Country
Poland
Facility Name
Centrum Medycyny Oddechowej, Mroz Spolka Jawna
City
Bialystok
ZIP/Postal Code
15-044
Country
Poland
Facility Name
Lekarze Specjalisci - J. Malolepszy i Partnerzy
City
Wroclaw
ZIP/Postal Code
54-239
Country
Poland
Facility Name
Hospital Universitario de Bellvitge
City
Barcelona
ZIP/Postal Code
08907
Country
Spain
Facility Name
Hospital General Universitario Gregorio Maranon (HGUGM) - Instituto de Investigacion Sanitaria Gregorio Maranon (IiSGM)
City
Madrid
ZIP/Postal Code
28007
Country
Spain
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD Sharing Time Frame
Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
IPD Sharing Access Criteria
Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (eg, FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
IPD Sharing URL
https://vivli.org/
Learn more about this trial
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
We'll reach out to this number within 24 hrs